Evidence map›Paper›PMID 39394145›Full record

ArticleCell death & disease2024

High mitochondrial DNA content is a key determinant of stemness, proliferation, cell migration, and cancer metastasis in vivo.

Marta Mauro-Lizcano, Filippo Di Pisa, Luis Larrea Murillo, Conor J Sugden, Federica Sotgia, Michael P Lisanti

Abstract read
In one paragraph

Article in Cell death & disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. The metabolic profiles of cancer stem cells.Stem cell research & therapy · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marta Mauro-Lizcano *Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, M5 4WT, UK.
Filippo Di Pisa *Translational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, M5 4WT, UK.
Luis Larrea MurilloTranslational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, M5 4WT, UK.ORCID 0000-0001-5634-7300
Conor J SugdenTranslational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, M5 4WT, UK.
Federica SotgiaTranslational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, M5 4WT, UK. fsotgia@gmail.com.
Michael P LisantiTranslational Medicine, School of Science, Engineering and Environment (SEE), University of Salford, Greater Manchester, M5 4WT, UK. michaelp.lisanti@gmail.com.ORCID 0000-0003-2034-1382

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we examined the potential role of mitochondrial DNA (mtDNA) levels in conveying aggressive phenotypes in cancer cells, using two widely-used breast cell lines as model systems (MCF7[ER+] and MDA-MB-231[ER-]). These human breast cancer cell lines were fractionated into mtDNA-high and mtDNA-low cell sub-populations by flow cytometry, using SYBR Gold as a vital probe to stain mitochondrial nucleoids in living cells. Enrichment of mtDNA-high and mtDNA-low cell sub-populations was independently validated, using a specific DNA-binding mAb probe (AC-30-10), and mitochondrial-based functional assays. As predicted, mtDNA-high MCF7 cells showed significant increases in mitochondrial mass, membrane potential, and superoxide production, as well as increased mitochondrial respiration and ATP production. Moreover, mtDNA-high MCF7 cells demonstrated increases in stemness features, such as anchorage-independent growth and CD44 levels, as well as drug-resistance to Gemcitabine and Tamoxifen. Proliferation rates were also significantly increased, with a dramatic shift towards the S- and G2/M-phases of the cell cycle; this was indeed confirmed by RNA-Seq analysis. Complementary results were obtained with MDA-MB-231 cells. More specifically, mtDNA-high MDA-MB-231 cells showed increases in stemness features and ATP production, as well as rapid cell cycle progression. Moreover, mtDNA-high MDA-MB-231 cells also exhibited increases in both cell migration and invasion, suggesting a role for mtDNA in distant metastasis. To test this hypothesis more directly, a preclinical in vivo model was utilized. For this purpose, MDA-MB-231 tumour cell grafts were treated with an established mtDNA synthesis inhibitor, namely Alovudine (3'-deoxy-3'-fluorothymidine). As expected, drug-induced depletion of mtDNA led to a shift from mitochondrial to glycolytic metabolism. Interestingly, Alovudine very effectively reduced the formation of spontaneous metastases by nearly 70%, but minimally inhibited tumour growth by approximately 20%. Taken together, these data suggest that high mtDNA content is a key driver of stemness, proliferation, and migration, as well as cancer cell metastasis.

Indexed as

Breast NeoplasmsCell MovementCell ProliferationDNA, MitochondrialNeoplasm MetastasisNeoplastic Stem CellsAnimalsCell Line, TumorDrug Resistance, NeoplasmFemaleHumansMCF-7 CellsMiceMitochondriaDNA, Mitochondrial

Identifiers

PMID39394145
PMCPMC11470112

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.